SMYD2 epigenetically activates BMP4/SMAD1/5/8/ID3 axis to enhance cancer stem cell properties and drive sorafenib resistance in hepatocellular carcinoma

SMYD2 epigenetically activates BMP4/SMAD1/5/8/ID3 axis to enhance cancer stem cell properties and drive sorafenib resistance in hepatocellular carcinoma

Background: Drug resistance prominently hampers the effects of sorafenib in hepatocellular carcinoma (HCC). Epigenetics play important roles in drug resistance. However, the contributions of SET And MYND Domain Containing 2 (SMYD2) to sorafenib resistance in HCC remain unknown. This study is aimed a...

Full description

Saved in:
Bibliographic Details
Main Authors: Shanshan Wang, Weicheng Wu, Zhen Shi, Mei Bin, Fengwei Zhang, Long Cai, Kaiqing Lin, Zhihui Li
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
SMYD2
Cancer stem cells
BMP4
Hepatocellular carcinoma
Sorafenib resistance
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558625000831
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S1476558625000831

Similar Items